PART 01: Executive summary
- Highlights
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
PART 05: Overview: Bacterial conjunctivitis
- Conjunctivitis
- Bacterial conjunctivitis
- Signs and symptoms
- Diagnosis
- Management
- Economic burden
PART 06: Pipeline analysis
- FST-100
- AzaSite Xtra (ISV-405)
PART 07: Antimicrobial resistance
- Initiatives to improve innovation of antibiotics
PART 08: Legislation relating to antibiotic use in US
PART 09: Market landscape
- Market overview
- Market size and forecast
- Bacterial conjunctivitis drugs market in US
- Five forces analysis
PART 10: Market segmentation by drug class
- Fluoroquinolones
- Aminoglycosides
- Macrolides
- Other
PART 11: Geographical segmentation
- Global bacterial conjunctivitis drugs market by geography 2015-2020
- Bacterial conjunctivitis drugs market in Americas
- Bacterial conjunctivitis drugs market in EMEA
- Bacterial conjunctivitis drugs market in APAC
PART 12: Market drivers
- Rising awareness about infection
- Development of multidrug-resistant variants
- Prevalence of bacterial conjunctivitis
PART 13: Impact of drivers
PART 14: Market challenges
- Patent expiry of drugs
- Contentment with existing therapies
- Adverse effects and limited efficacy of drugs
- Weak R&D of drugs
PART 15: Impact of drivers and challenges
PART 16: Market trends
- Strategic alliances and M&A
- Use of combination therapies
- Patient assistance programs
PART 17: Vendor landscape
- Competitive scenario
- Akorn
- Alcon
- Allergan
- Bausch & Lomb
- Other prominent vendors
PART 18: Appendix
- List of abbreviations
PART 19: Explore Technavio



List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Types of conjunctivitis
Exhibit 03: Types of bacterial conjunctivitis
Exhibit 04: Signs and symptoms of bacterial conjunctivitis
Exhibit 05: Drugs used to treat conjunctivitis
Exhibit 06: Global bacterial conjunctivitis drugs market: Pipeline portfolio
Exhibit 07: Causes of antimicrobial resistance
Exhibit 08: Initiatives improving antibiotic innovation
Exhibit 09: Legislation relating to antibiotic use in US
Exhibit 10: Global bacterial conjunctivitis drugs market 2015-2020 ($ billions)
Exhibit 11: Snapshot of global bacterial conjunctivitis drugs market
Exhibit 12: Percentage share of bacterial conjunctivitis drugs market in US
Exhibit 13: Bacterial conjunctivitis drugs market in US 2015-2020 ($ millions)
Exhibit 14: Five forces analysis
Exhibit 15: Global bacterial conjunctivitis drugs market by drug class
Exhibit 16: Global bacterial conjunctivitis drugs market by geography 2015
Exhibit 17: Global bacterial conjunctivitis drugs market by geography 2015-2020 ($ billions)
Exhibit 18: Bacterial conjunctivitis drugs market in Americas 2015-2020 ($ millions)
Exhibit 19: Bacterial conjunctivitis drugs market in EMEA 2015-2020 ($ millions)
Exhibit 20: Bacterial conjunctivitis drugs market in APAC 2015-2020 ($ millions)
Exhibit 21: Global bacterial conjunctivitis drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 22: Key drivers
Exhibit 23: Impact of drivers
Exhibit 24: Key challenges
Exhibit 25: Impact of drivers and challenges
Exhibit 26: Key trends
Exhibit 27: Akorn: YoY growth and revenues in ophthalmic segment 2011-2013 ($ millions)
Exhibit 28: Akorn: Key takeaways
Exhibit 29: Business segmentation by revenue 2014
Exhibit 30: Alcon: YoY growth and revenue generated from sales of ophthalmic products 2011-2014 ($ billions)
Exhibit 31: Alcon: Key takeaways
Exhibit 32: Allergan: Key takeaways
Exhibit 33: Bausch & Lomb: Key takeaways